Dr Elena Pontarini
/filters:format(webp)/prod01/channel_144/whri/media/the-william-harvey-research-institute/staff-and-students/research-staff/Pontarini,-E-300X300.jpg)
Senior Lecturer in Immunology
Centre: Experimental Medicine and Rheumatology
Email: elena.pontarini@qmul.ac.uk
Profile
ORCID ID: 0000-0003-0439-0344
Elena Pontarini is a translational immunologist investigating why the immune system attacks the body’s own tissues in rheumatic autoimmune diseases, such as the salivary glands in Sjögren’s disease and the synovium in rheumatoid arthritis, and how to stop it.
She trained in Biological Sciences and Medical Biotechnology at the University of Udine and completed her PhD in Immunology and Immunopathology at the Humanitas Research Institute, Milan. She joined Prof Michele Bombardieri’s group at EMR in 2016, established her independent research with a Versus Arthritis Foundation Fellowship (2018–2021), became Lecturer in 2020 and was promoted to Senior Lecturer in 2025.
She leads the Sjögren’s disease programme in the MSK theme of the NIHR Barts Biomedical Research Centre and is WHRI Academic Lead for the BCI–WHRI Charterhouse Square Flow Cytometry Facility. She has published over 50 peer-reviewed papers (h-index 30, Google Scholar), including in Annals of the Rheumatic Diseases, Nature Metabolism, JCI and Lancet Rheumatology.
She is an abstract reviewer and session chair for EULAR (European Alliance of Associations for Rheumatology) and a Review Editor for Frontiers in Immunology.
Research
Group members
- Dr Kunjan Harit (Postdoctoral researcher)
- Nikitha Meyyameena Palaniappan (PhD student, Advanced AI for Multi-modal Spatial Biology PhD Programme)
- Marta Sobrado (PhD student, Research nurse)
Summary
Sjögren’s disease is a common autoimmune disease that damages the exocrine glands, such as the salivary and tear glands. It carries one of the highest lymphoma risks of any autoimmune condition, at least ten times that of the general population, and still has no approved disease-modifying treatment. Our group studies how immune cells organise inside the inflamed gland and which of them drive chronic B-cell activation and increase the risk of lymphoma. Our aims are to understand disease heterogeneity, stratify patients and identify effective treatment targets.
- T-cell help and lymphoma: we discovered that IL-21+ T follicular helper (Tfh) and T peripheral helper (Tph) cells expand in Sjögren’s disease with ectopic germinal centres and MALT lymphoma (Pontarini et al., ARD 2020). We are now testing them as therapeutic targets and biomarkers.
- Pre-malignant lesions: we investigate how epithelial LAMP3 drives B-cell activation in lymphoepithelial lesions, using epithelial–B-cell co-culture models.
- Patient stratification: salivary gland transcriptomics links tissue signatures to autoantibody status (ARD 2025) and to treatment response in clinical trials (TRACTISS, NECESSITY).
- Beyond inflammation: the mechanisms of small fibre neuropathy and of NGF/NGFR-driven gland dysfunction.
Approach: high-dimensional flow cytometry, single-cell and spatial profiling, digital pathology and AI, multi-omics of clinical-trial cohorts, and salivary gland organ cultures. Our open web tools let anyone explore the QMUL Sjögren’s cohort and the TRACTISS trial.
Publications
-
Chevet B, Devauchelle-Pensec V, Pontarini E et al. (2026). Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease. nameOfConference
-
Chatzis LG, Pontarini E, Fulvio G et al. (2025). Evolving mechanisms in the pathogenesis of Sjögren's disease: one year in review 2025.. nameOfConference
QMRO: qmroHref -
Duquesne J, Basseto L, Claye C et al. (2025). Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort study. nameOfConference
-
Pontarini E, Lucchesi D, Sciacca E et al. (2025). Transcriptomic profiling of Sjögren’s disease salivary glands identifies signatures associated with both follicular and extrafollicular responses linked to rheumatoid factor and anti-La/SSB seropositivity. nameOfConference
-
Certo M, Pontarini E, Gilbert SG et al. (2025). Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution. nameOfConference
-
Rivellese F, Pontarini E, Fossati‐Jimack L et al. (2025). Comparative Analysis of Circulating and Synovial Immune Cells in Early Untreated Rheumatoid Arthritis and Their Relationship With Molecular Pathology and Disease Outcomes. nameOfConference
DOI: 10.1002/art.43194
-
Gallagher-Syed A, Senior H, Alwazzan O et al. (2025). BioX-CPath: Biologically-driven Explainable Diagnostics for Multistain IHC Computational Pathology. 2025 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR)
-
Bowman SJ, Seror R, Porcher R et al. (2025). Primary Sjögren’s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI). nameOfConference
QMRO: qmroHref -
Chevet B, Devauchelle-Pensec V, Pontarini E et al. (2025). OP0145 TRANSCRIPTOMIC STRATIFICATION PREDICTS RESPONSE TO RITUXIMAB, ABATACEPT OR THE ASSOCIATION OF HYDROXYCHLOROQUINE AND LEFLUNOMIDE IN 3 RANDOMIZED CONTROLLED CLINICAL TRIALS IN SJÖGREN'S DISEASE. nameOfConference
Sponsors
Charity and public: Versus Arthritis; Barts Charity; NIHR Barts Biomedical Research Centre; British Sjögren’s Syndrome Association; EULAR; EU IMI/IHI (NECESSITY and LOTUS consortium)
Industry: GSK; Bristol Myers Squibb; Dompé farmaceutici
Collaborators
External
- Dr John Chiorini (NIH, USA)
- Dr Claudia Mauri (UCL, London)
- Dr Gwenny Verstappen and Prof Hendrika Bootsma (University of Groningen)
- Prof Xavier Mariette and Dr Gaetane Nocturne (Université Paris-Saclay)
- Prof Claudio Mauro (University of Birmingham)
- Dr Daniele Mauro (University of Naples Federico II)
- Dr Serena Colafrancesco (University of Milan)
Internal
- Dr Marta Sallan (Barts Cancer Institute)
Teaching
- Module Lead: MSK Inflammation, Immunology and Immunopathology – MSc Precision MSK Science
- Lecturer and examiner: Basic Immunology and Immunopathology (MSc); Translational Pharmacology and Innovative Therapeutics (BMD375, BSc Year 3); Basic Immunology (BMD251, Year 2)
- PBL facilitator: Year 2
- Supervision: PhD, DClinDent, intercalated BSc and visiting doctoral fellows
Disclosures
No disclosures.